ABIO ARCA biopharma Inc

Price (delayed)

$3.02

Market cap

$43.52M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.61

Enterprise value

-$19.24M

ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically ...

Highlights
ARCA biopharma's EPS has increased by 47% YoY and by 20% from the previous quarter
The company's quick ratio has surged by 106% YoY but it fell by 26% QoQ
ARCA biopharma's net income has decreased by 28% QoQ
The company's debt rose by 10% QoQ

Key stats

What are the main financial stats of ABIO
Market
Shares outstanding
14.41M
Market cap
$43.52M
Enterprise value
-$19.24M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.71
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$16.05M
EBITDA
-$15.97M
Free cash flow
-$13.98M
Per share
EPS
-$1.61
Free cash flow per share
-$0.97
Book value per share
$4.25
Revenue per share
$0
TBVPS
$4.53
Balance sheet
Total assets
$65.34M
Total liabilities
$4.13M
Debt
$435,000
Equity
$61.21M
Working capital
$61.1M
Liquidity
Debt to equity
0.01
Current ratio
17.54
Quick ratio
17.1
Net debt/EBITDA
3.93
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-27.1%
Return on equity
-28.6%
Return on invested capital
N/A
Return on capital employed
-26%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABIO stock price

How has the ARCA biopharma stock price performed over time
Intraday
0%
1 week
-2.58%
1 month
-0.98%
1 year
-25.8%
YTD
-24.69%
QTD
-13.47%

Financial performance

How have ARCA biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.06M
Net income
-$16.05M
Gross margin
N/A
Net margin
N/A
ARCA biopharma's net income has decreased by 28% QoQ
ABIO's operating income is down by 28% since the previous quarter

Growth

What is ARCA biopharma's growth rate over time

Valuation

What is ARCA biopharma stock price valuation
P/E
N/A
P/B
0.71
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ARCA biopharma's EPS has increased by 47% YoY and by 20% from the previous quarter
ABIO's price to book (P/B) is 29% lower than its 5-year quarterly average of 1.0
The company's equity fell by 7% QoQ

Efficiency

How efficient is ARCA biopharma business performance
The return on equity has surged by 53% year-on-year
ARCA biopharma's return on assets has increased by 49% YoY

Dividends

What is ABIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABIO.

Financial health

How did ARCA biopharma financials performed over time
The company's quick ratio has surged by 106% YoY but it fell by 26% QoQ
The company's current ratio has surged by 101% YoY but it fell by 26% QoQ
The company's debt is 99% lower than its equity
The company's debt rose by 10% QoQ
The company's equity fell by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.